Evaluation of T Cell Response to Cisplatin Resistant NSCLC

T 细胞对顺铂耐药 NSCLC 的反应评估

• 批准号: 8625606
• 负责人: JOHN R. YANNELLI
• 金额: $ 7.5万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8625606
• 关键词: Accounting; Address; Adjuvant; Advocate; Allogenic; Anatomic Sites; Antigens; Apoptotic; Archives; Autologous Dendritic Cells; Brain; Breast; CD8B1 gene; Cancer Patient; Cancer cell line; Cell Line; Cell Survival; Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Characteristics; Cisplatin; Clinic; Clinical Research; Colon; Colon Carcinoma; Cytotoxic T-Lymphocytes; Data; Disease; Drug Targeting; Drug resistance; Drug toxicity; Effectiveness; Evaluation; Exposure to; Failure; Family; Flow Cytometry; Frequencies; Funding; Future; Growth; HLA-A2 Antigen; Habits; Healthcare Systems; Household; Immune response; Immune system; Immunity; Immunotherapeutic agent; Immunotherapy; In Vitro; Injection of therapeutic agent; Investigation; Kentucky; Laboratories; Lead; Link; Literature; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Methodology; Necrosis; Non-Small-Cell Lung Carcinoma; Oncologist; Operative Surgical Procedures; Outcome; Patients; Peptides; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Phenotype; Play; Population; Primary Health Care; Prostate; Proteins; Quality of life; Radiation; Radiation therapy; Reagent; Recurrence; Resistance; Rest; Role; Site; Smoke; Smoking; Societies; Solid Neoplasm; Source; Specificity; Staging; Supportive care; Survival Rate; Symptoms; T cell response; T-Lymphocyte; Taxes; Therapeutic; Tumor Antigens; Universities; Vaccine Therapy; Vaccines; Variant; Woman; base; beta-Glucans; bone; chemotherapeutic agent; chemotherapy; conventional therapy; design; disease diagnosis; immunogenic; immunogenicity; improved; lymph nodes; malignant breast neoplasm; men; neoplastic cell; never smoker; novel; novel vaccines; outcome forecast; patient population; prevent; public health relevance; research clinical testing; tumor; vaccine development; vaccine evaluation

Abstract: Non small cell lung cancer (NSCLC) is a leading killer of men and women around the world. Most patients present in the clinic with advanced stage disease at a point where surgery is not an option and conventional chemotherapy and radiation therapy are limited in their effectiveness. Novel therapies are needed for this patient population. Continued failure to significantly impact NSCLC patients with conventional therapy will tax the health care system and remain a financial burden for families and society. Interestingly, while NSCLC is responsive to chemotherapeutic agents such as cisplatin, tumor is often observed to recur or progress in additional anatomic sites. It is known that NSCLC, as well as other solid tumors, develop mechanisms of drug resistance. Thus, continued exposure to cisplatin remains ineffective. In the current study, we propose to investigate whether Immunotherapy, which exploits the patient's immune system to recognize and eliminate cancer, should be considered to address the issue of chemo-resistance. We are asking the question that following cisplatin therapy in NSCLC patients, what role can immunotherapy play in preventing the growth of chemo-resistant tumor cell clones which likely result in tumor recurrence and progression? Our hypothesis is that proteins which characterize cisplatin chemo-resistance can be targeted by vaccine therapy. To address this hypothesis we will build on the expertise of our group in developing and delivering vaccines in lung cancer. The current proposal is a proof of principle study which will investigate the existence of novel shared tumor associated antigens which are immunogenic and define the chemo-resistant phenotype. A unique methodology is proposed to identify HLA-A2 restricted cisplatin resistant CTL in normal donors based on specific antigen stimulation and TCR-Vbeta analysis. Understanding preferential usage of Vbetas in normal donors will be applied to the analysis of archived PBMC derived from -A2+ patients with NSCLC. Using this methodology, we will determine if the precursor frequency for CTL specific for peptides characteristic of the cisplatin resistant state will be higher in patients previously exposed to cisplatin. If true, in a future clinical study, we hypothesize that NSCLC patients can be immunized against these peptides before cisplatin therapy. Following an appropriate period of rest, NSCLC patients given boost vaccine injections with the peptides derived from the chemo-resistant proteins are expected to generate a potent immune response allowing the recognition and destruction of chemo-resistant tumor cells; thus preventing recurrence and progression. All required reagents for this proof of principle analysis are available to the applicant.

摘要：非小细胞肺癌（NSCLC）是全球男性和女性的主要杀手。大多数